- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Targeted therapy for HER2 positive breast cancer ; volume:6 ; number:1 ; day:3 ; month:6 ; year:2013 ; pages:1-9 ; date:12.2013
Journal of hematology & oncology ; 6, Heft 1 (3.6.2013), 1-9, 12.2013
- Creator
-
Incorvati, Jason A.
Shah, Shilpan
Mu, Ying
Lu, Janice
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-6-38
- URN
-
urn:nbn:de:101:1-2021082821111792646269
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
16.04.2025, 8:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Incorvati, Jason A.
- Shah, Shilpan
- Mu, Ying
- Lu, Janice
- SpringerLink (Online service)
Other Objects (12)
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
HER2-targeted therapy influences CTC status in metastatic breast cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
HER2-targeted therapy influences CTC status in metastatic breast cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
HER2-targeted therapy influences CTC status in metastatic breast cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy